肝动脉化疗栓塞术联合仑伐替尼治疗中晚期肝细胞肝癌的临床疗效及安全性分析  

Analysis of the clinical efficacy and safety of hepatic artery chemoembolization combined with lenvatinib in the treatment of advanced hepatocellular carcinoma

作　　者：刘娟 廖豪杰 袁国盛 梁敏峰 黄维[5] 高雪萍 蓝云翠 林占洲[1] LIU Juan;LIAO Hao-jie;YUAN Guo-sheng;LIANG Min-feng;HUANG Wei;GAO Xue-ping;LAN Yun-cui;LIN Zhan-zhou(Department of Hepatology,Huizhou Central People′s Hospital,Huizhou 516001,China;Department of Oncology,Huizhou Central People′s Hospital,Huizhou 516001,China;Department of Liver Cancer Unit,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Infectious Diseases,Foshan First People′s Hospital,Foshan 528000,China;Department of Oncology,Shunde People′s Hospital,Foshan 528300,China)

机构地区：[1]广东省惠州市中心人民医院肝病内科,广东惠州516001 [2]广东省惠州市中心人民医院肿瘤内科,广东惠州516001 [3]南方医科大学南方医院肝脏肿瘤中心,广东广州510515 [4]广东省佛山市第一人民医院感染科,广东佛山528000 [5]广东省佛山市顺德第一人民医院肿瘤内科,广东佛山528300

出　　处：《实用医院临床杂志》2022年第1期55-59,共5页Practical Journal of Clinical Medicine

基　　金：广东省自然科学基金面上项目(编号:2021A1515012518);南方医科大学南方医院临床研究专项基金资助(编号:2020CR021)。

摘　　要：目的比较肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)联合仑伐替尼与TACE单独治疗中晚期肝细胞肝癌(HCC)的临床疗效及安全性。方法收集4家医院HCC患者的临床资料,并根据治疗方式分为TACE联合仑伐替尼组52例和TACE治疗组51例。比较两组患者的肿瘤应答情况、生存情况及不良反应。结果联合组的客观缓解率(ORR)和疾病控制率(DCR)均显著高于TACE组(P<0.001)。两组患者的中位无疾病进展时间(PFS)分别为8.1和4.2个月,差异有统计学意义(P<0.05);中位总体生存时间(OS)分别为17.8和10.1个月,差异有统计学意义(P<0.05)。随访过程中的不良反应均为I~II度,予对症处理后均得到有效控制。结论仑伐替尼联合TACE方案可有效延长中晚期HCC患者生存期,且耐受性良好。Objective To compare the efficacy and tolerability of transcatheter arterial chemoembolization(TACE)combined with lenvatinib to those of TACE alone in patients with advanced hepatocellular carcinoma(HCC).Methods We retrospectively analyzed the data of advanced HCC patients who underwent TACE-Lenvatinib or TACE alone in 4 hospitals.The patients were divided into a TACE-Lenvatinib group(n=52)and a TACE group(n=51)according to the treatment method.Tumor responses and tolerability of TACE-Lenvatinib treatment were compared with those of TACE alone treatment.Overall survival was also compared by using the Kaplan-Meier analysis.Results The objective response rate(ORR)and disease control rate(DCR)in the TACE-Lenvatinib group were higher than those in the TACE group(P<0.001).The median progressive free survival(PFS)was 8.1 months in the TACE-Lenvatinib group and 4.2 months in the TACE group(P<0.05).The median overall survival(OS)was 17.8 months in the TACE-Lenvatinib group and 10.1 months in the TACE group(P<0.05).The adverse reactions during the follow-up process were all grade I~II,which were effectively controlled after symptomatic treatment.Conclusion Lenvatinib combined with TACE regimen can effectively prolong the survival time of patients with advanced HCC.It is also well tolerated.

关 键 词：肝细胞肝癌 肝动脉化疗栓塞术 仑伐替尼 临床疗效 安全性 

分 类 号：R735.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]